Poster 2

Investigating the influence of human serum albumin concentration on (Z)-4-hydroxytamoxifen treatment of ER positive breast cancer

Authors: Marialuisa Berghela, Dylan Mattison, Wen Tan Lu, Ian Jin, Kideok Jin, Marcel Musteata

Presenting Author: Marialuisa Berghela

Affiliation: Albany College of Pharmacy and Health Sciences **Corresponding Author's email:** Marialuisa.Berghela@acphs.edu

Purpose

Serum albumin is a major facilitator of drug transport. However, little is known about the interactions between serum albumin and (Z)-4-hydroxytamoxifen (4OHT) during treatment. The purpose of this study is to explore the influence of serum album concentration on 4OHT's effectiveness in treating ER positive breast cancer.

Methods

A pumping system that mimics the circulatory system and blood flow of organs in a mouse has been designed. Two peristatic pumps were used; one that acts as the liver/kidney elimination system and another that acts as the diseased tissue blood flow, all connected by silicon tubing. A T-25 cell flask acts as a cell compartment that allows for diseased cells to be added into the system. Two parallel systems were used under identical conditions; one is treated with a drug, while another acts as a control.

Once the pumping system was running with cell culture media (no cells), injections of 56 uL 4OHT (5 mg/mL) were performed daily to identify the ideal pumping rates to yield the correct half-life of the drug. A daily injection of 56 uL 4OHT was given and 10 uL samples were taken every 30 minutes to 1 hour. To prepare a sample for LC-MS analysis, 190 uL water and 400 uL acetonitrile with internal standard were added to the 10 uL sample. The mixture was then vortexed at 2000 RPM and centrifuged at 15,000 RPM for 30 minutes. 100 uL of supernatant was transferred to a total recovery vial, labeled with the collection time, and analyzed via LC-MS.

MCF-7, ER positive breast cancer cells were seeded into the T-25 flasks and placed into the system (2g/L serum albumin). A daily injection of 112 uL 4OHT was injected for 3 days in the experimental system. The control system received blank injections. The crystal violet staining assay was performed to assess the cell viability of the treated and non-treated cells.

Results

The LC-MS data shows the 4OHT concentration in the system when the sample was collected. The data were plotted, and the half-life was derived from the slope of the line as being around half a day. The optimal flow rate was determined to be 0.05 mL/min for the elimination pump and 1 mL/min for the diseased tissue pump. Upon analysis of the crystal violet staining assay, there was less MCF-7 cell survival in the 4OHT treated cells, proving that the system was successful in administering the treatment and the treatment was effective in killing the MCF-7 breast cancer cells.

Conclusion

This fluidic system has proven to be suitable in testing treatments with cells and successful in mimicking the circulatory system of a mouse. Further studies include repeating experiments at various concentrations of serum albumin to determine its influence on 4OHT treatment of ER positive breast cancer.

Keywords: serum albumin, (Z)-4-hydroxytamoxifen, ER positive breast cancer